Denise Mann is a freelance health writer based in New York. With extensive experience covering a range of topics including medicine and healthcare, beauty and fashion, and public health, she brings a wealth of knowledge to her work, which has been featured in outlets such as HealthDay News and Reader's Digest. Denise's contributions to journalism have been recognized with multiple awards, including the Excellence in Women's Health Research Journalism Award and the 2011 National Newsmaker of the Year by the Community Anti-Drug Coalitions of America.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Denise Mann's coverage predominantly focuses on healthcare, pharmaceuticals, and scientific topics related to dermatology and skin conditions. The majority of her articles cite data or are based on press releases. She appears to be interested in reporting on the latest medical research, FDA approvals, and developments within the field of skincare.
When reaching out to Denise Mann with pitches or expert commentary, consider offering access to new research findings, exclusive insights into clinical trials for dermatological treatments or FDA approval processes. Providing access to experts who can offer unique perspectives on emerging trends in dermatology and skin care could also be well received by Denise.
Given that there is no specified geographic focus for Denise Mann's work, she may cover global developments within dermatology and skin care fields.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Denise Mann
Recognizing a possible syndrome linking acne keloidalis nuchae (AKN), scalp-wide dissecting cellulitis (DCS) and secondary cutis verticis gyrata (CVG) may lead to more effective treatment. This is the main takeaway from new research in Clinical, Cosmetic and Investigational Dermatology. For the study, researchers reviewed 12 consecutive men with suspected or confirmed DCS at one Los Angeles […]
No parabens, no phthalates, no compromises, just seven products built for the most sensitive skin there is.
Sciton Inc. is launching Super MOXI with High Density (HD) Delivery, an evolution of its MOXI laser. Harnessing the power of twin beams for treatments up to twice as fast and a more powerful 16W diode to efficiently treat larger areas, Super MOXI with HD Delivery is available on the portable mJOULE and JOULE X […]
By: Denise Mann
SkinMedica is launching NEW Barrier Calming Cream and NEW HA5 Hydra Collagen Facial Mist with Vegan Collagen.
By: Denise Mann
New research from Allergan Aesthetics documents a shift away from one-off treatments toward more personalized, long-term aesthetic plans around the globe, with some differences in how consumers across markets are approaching beauty and aesthetics. The Layered Beauty: The New Aesthetic Mindset report, surveyed more than 12,000 beauty-involved consumers across nine markets. Across markets, consumers are […]
By: Denise Mann
DermaSensor Inc. is expanding its U.S. commercial strategy through a series of strategic partnerships to accelerate adoption of its US Food and Drug Administration (FDA)-cleared, handheld skin cancer detection device across primary care, enterprise healthcare, and federal healthcare systems. The DermaSensor device is a non-invasive, handheld system that uses artificial intelligence and spectroscopy to immediately […]
No two people in the world have the same color eyes. Experts weigh in on the genetics that cause the rarest eye color in the world...plus, what can cause our eye color to change.
Research suggests that telltale symptoms may appear before cardiac arrest, and knowing how to recognize them can be lifesaving.
By: Denise Mann
A timely diagnostic workup is warranted in adults with suspected atopic dermatitis (AD) who fail to respond to optimized, guideline-recommended care, with clinical expertise guiding the selection of appropriate tests. This is the main message from a new Good Practice Statement on the diagnostic workup of adults with presumed AD unresponsive to therapy in the […]
By: Denise Mann
Some people with chronic cutaneous lupus erythematosus may be less likely to acquire life-threatening infections when taking the drug anifrolumab (Saphnelo, AstraZeneca). Published in the Journal of the European Academy of Dermatology and Venereology (JEADV), the findings highlight how anifrolumab can provide distinct benefits over the use of conventional immunosuppressants in patients with treatment-resistant chronic […]
